38 results on '"Coupé, Veerle M. H."'
Search Results
2. A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework
- Author
-
Kunst, Natalia, Burger, Emily A., Coupé, Veerle M. H., Kuntz, Karen M., and Aas, Eline
- Published
- 2024
- Full Text
- View/download PDF
3. A Bayesian accelerated failure time model for interval censored three-state screening outcomes
- Author
-
Klausch, Thomas, Akwiwu, Eddymurphy U., van de Wiel, Mark A., Coupe, Veerle M. H., and Berkhof, Johannes
- Subjects
Statistics - Methodology ,62N02 - Abstract
Women infected by the Human papilloma virus are at an increased risk to develop cervical intraepithalial neoplasia lesions (CIN). CIN are classified into three grades of increasing severity (CIN-1, CIN-2, and CIN-3) and can eventually develop into cervical cancer. The main purpose of screening is detecting CIN-2 and CIN-3 cases which are usually surgically removed. Screening data from the POBASCAM trial involving 1,454 HPV-positive women is analyzed with two objectives: estimate (a) the transition time from HPV diagnosis to CIN-3; and (b) the transition time from CIN-2 to CIN-3. The screening data have two key characteristics. First, the CIN state is monitored in an interval-censored sequence of screening times. Second, a woman's progression to CIN-3 is only observed, if the woman progresses to, both, CIN-2 and from CIN-2 to CIN-3 in the same screening interval. We propose a Bayesian accelerated failure time model for the two transition times in this three-state model. To deal with the unusual censoring structure of the screening data, we develop a Metropolis-within-Gibbs algorithm with data augmentation from the truncated transition time distributions., Comment: 22 pages (Manuscript), 34 pages (Supplemental Material)
- Published
- 2021
4. Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial
- Author
-
Swartjes, Hidde, Qaderi, Seyed M., Teerenstra, Steven, Custers, Jose A. E., Elferink, Marloes A. G., van Wely, Bob J., Burger, Jacobus W. A., van Grevenstein, Wilhelmina M. U., van Duijvendijk, Peter, Verdaasdonk, Emiel G. G., de Roos, Marnix A. J., Coupé, Veerle M. H., Vink, Geraldine R., Verhoef, Cornelis, and de Wilt, Johannes H. W.
- Published
- 2023
- Full Text
- View/download PDF
5. Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
- Author
-
Mfumbilwa, Zakile A., Wilschut, Janneke A., Simons, Martijn J. H. G., Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M. Cramer-van, Schramel, Franz M. N. H., van de Garde, Ewoudt M. W., and Coupé, Veerle M. H.
- Published
- 2023
- Full Text
- View/download PDF
6. The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study
- Author
-
Wisse, Pieter H A, de Klaver, Willemijn, van Wifferen, Francine, van Maaren-Meijer, Frejanne G, van Ingen, Huub E, Meiqari, Lana, Huitink, Iris, Bierkens, Mariska, Lemmens, Margriet, Greuter, Marjolein J E, van Leerdam, Monique E, Spaander, Manon C W, Dekker, Evelien, Coupé, Veerle M H, Carvalho, Beatriz, de Wit, Meike, and Meijer, Gerrit A
- Published
- 2024
- Full Text
- View/download PDF
7. KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer
- Author
-
Uil, Sjoerd H., Coupé, Veerle M. H., Bril, Herman, Meijer, Gerrit A., Fijneman, Remond J. A., and Stockmann, Hein B. A. C.
- Published
- 2022
- Full Text
- View/download PDF
8. Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.
- Author
-
Kramer, Astrid, Greuter, Marjolein J. E., Schraa, Suzanna J., Vink, Geraldine R., Phallen, Jillian, Velculescu, Victor E., Meijer, Gerrit A., van den Broek, Daan, Koopman, Miriam, Roodhart, Jeanine M. L., Fijneman, Remond J. A., Retèl, Valesca P., and Coupé, Veerle M. H.
- Abstract
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating tumor DNA (ctDNA) could improve patient selection for ACT. Objectives: We conducted an early model-based evaluation of the (cost-)effectiveness of ctDNA-guided selection for ACT in stage II CC in the Netherlands to assess the conditions for cost-effective implementation. Methods: A validated Markov model, simulating 1000 stage II CC patients from diagnosis to death, was supplemented with ctDNA data. Five ACT selection strategies were evaluated: the current guideline (pT4, pMMR), ctDNA-only, and three strategies that combined ctDNA status with pT4 and pMMR status in different ways. For each strategy, the costs, life years, quality-adjusted life years (QALYs), recurrences, and CC deaths were estimated. Sensitivity analyses were performed to assess the impact of the costs of ctDNA testing, strategy adherence, ctDNA as a predictive biomarker, and ctDNA test performance. Results: Model predictions showed that compared to current guidelines, the ctDNA-only strategy was less effective (+2.2% recurrences, −0.016 QALYs), while the combination strategies were more effective (−3.6% recurrences, +0.038 QALYs). The combination strategies were not cost-effective, since the incremental cost-effectiveness ratio was €67,413 per QALY, exceeding the willingness-to-pay threshold of €50,000 per QALY. Sensitivity analyses showed that the combination strategies would be cost-effective if the ctDNA test costs were lower than €1500, or if ctDNA status was predictive of treatment response, or if the ctDNA test performance improved substantially. Conclusion: Adding ctDNA to current high-risk clinicopathological features (pT4 and pMMR) can improve patient selection for ACT and can also potentially be cost-effective. Future studies should investigate the predictive value of post-surgery ctDNA status to accurately evaluate the cost-effectiveness of ctDNA testing for ACT decisions in stage II CC. Plain language summary: Effectiveness and cost-effectiveness of circulating tumour DNA-guided selection for adjuvant chemotherapy in patients with stage II colon cancer Most patients with stage II colon cancer (CC) are cured by surgery. Therefore, guidelines recommend to only offer adjuvant chemotherapy to patients who have a tumor with high-risk features. However, current selection is suboptimal, leading to recurrence of cancer in 13% of low-risk patients and unnecessary administration of chemotherapy in some high-risk patients. Previous studies indicate that a biomarker, so-called circulating tumour DNA (ctDNA), could improve the selection of high-risk patients for adjuvant chemotherapy, as patients who have detectable ctDNA in their blood after surgery are likely to develop a recurrence. Despite its potential, implementation is still pending. Our study assessed the long-term effectiveness and costs associated with various ctDNA-guided strategies for selecting high-risk patients for adjuvant chemotherapy in stage II CC. We used an health-economic model to simulate a cohort of 1000 Dutch patients with stage II CC from diagnosis to death. Next, we compared the health outcomes and costs of the ctDNA-guided strategies to those when selection is based on the Dutch guideline. We found that a combination of the Dutch guideline and ctDNA was the most effective strategy, but not cost-effective. Additional analyses showed that ctDNA-guided selection were cost-effective if the costs of the ctDNA test were below 1500 euros, if the ctDNA test performed significantly better, or if patients with detectable ctDNA responded better to chemotherapy. Thus, while post-surgery ctDNA status is a good indicator for recurrence risk, specific criteria related to ctDNA test performance and costs, in addition to combining ctDNA with current high-risk features, should be met to achieve cost-effective implementation. Looking ahead, future studies should explore how patients with detectable ctDNA respond to chemotherapy for next assessments of the cost-effectiveness of ctDNA-guided strategies in selecting patients with stage II CC for adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
- Author
-
Simons, Martijn J. H. G., Retèl, Valesca P., Ramaekers, Bram L. T., Butter, Rogier, Mankor, Joanne M., Paats, Marthe S., Aerts, Joachim G. J. V., Mfumbilwa, Zakile A., Roepman, Paul, Coupé, Veerle M. H., Uyl-de Groot, Carin A., van Harten, Wim H., and Joore, Manuela A.
- Published
- 2021
- Full Text
- View/download PDF
10. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles
- Author
-
Bresalier, Robert S, primary, Senore, Carlo, additional, Young, Graeme P, additional, Allison, James, additional, Benamouzig, Robert, additional, Benton, Sally, additional, Bossuyt, Patrick M M, additional, Caro, Luis, additional, Carvalho, Beatriz, additional, Chiu, Han-Mo, additional, Coupé, Veerle M H, additional, de Klaver, Willemijn, additional, de Klerk, Clasine Maria, additional, Dekker, Evelien, additional, Dolwani, Sunil, additional, Fraser, Callum G, additional, Grady, William, additional, Guittet, Lydia, additional, Gupta, Samir, additional, Halloran, Stephen P, additional, Haug, Ulrike, additional, Hoff, Geir, additional, Itzkowitz, Steven, additional, Kortlever, Tim, additional, Koulaouzidis, Anastasios, additional, Ladabaum, Uri, additional, Lauby-Secretan, Beatrice, additional, Leja, Mārcis, additional, Levin, Bernard, additional, Levin, Theodore Robert, additional, Macrae, Finlay, additional, Meijer, Gerrit A, additional, Melson, Joshua, additional, O'Morain, Colm, additional, Parry, Susan, additional, Rabeneck, Linda, additional, Ransohoff, David F, additional, Sáenz, Roque, additional, Saito, Hiroshi, additional, Sanduleanu-Dascalescu, Silvia, additional, Schoen, Robert E, additional, Selby, Kevin, additional, Singh, Harminder, additional, Steele, Robert J C, additional, Sung, Joseph J Y, additional, Symonds, Erin Leigh, additional, and Winawer, Sidney J, additional
- Published
- 2023
- Full Text
- View/download PDF
11. A Bayesian accelerated failure time model for interval censored three-state screening outcomes
- Author
-
Klausch, Thomas, primary, Akwiwu, Eddymurphy U., additional, van de Wiel, Mark A., additional, Coupé, Veerle M. H., additional, and Berkhof, Johannes, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Abstract A004: Molecular adenoma features to predict metachronous colorectal cancer risk: A nested-case control study
- Author
-
Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., additional, Leon, Leticia G., additional, Lemmens, Margriet, additional, Delis-van Diemen, Pien, additional, Klotz, Dagmar, additional, de Wit, Meike, additional, Fijneman, Remond, additional, van Leerdam, Monique, additional, Dekker, Evelien, additional, Spaander, Manon C. W., additional, Meijer, Gerrit A., additional, Bretthauer, Michael, additional, Løberg, Magnus, additional, Coupé, Veerle M. H., additional, Kalager, Mette, additional, and Carvalho, Beatriz, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Cost-Utility of the eHealth Application ‘Oncokompas’, Supporting Incurably Ill Cancer Patients to Self-Manage Their Cancer-Related Symptoms: Results of a Randomized Controlled Trial
- Author
-
Schuit, Anouk S., primary, Holtmaat, Karen, additional, Coupé, Veerle M. H., additional, Eerenstein, Simone E. J., additional, Zijlstra, Josée M., additional, Eeltink, Corien, additional, Becker-Commissaris, Annemarie, additional, van Zuylen, Lia, additional, van Linde, Myra E., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Sommeijer, Dirkje W., additional, Verbeek, Nol, additional, Bosscha, Koop, additional, Nandoe Tewarie, Rishi, additional, Sedee, Robert-Jan, additional, de Bree, Remco, additional, de Graeff, Alexander, additional, de Vos, Filip, additional, Cuijpers, Pim, additional, Verdonck-de Leeuw, Irma M., additional, and Jansen, Femke, additional
- Published
- 2022
- Full Text
- View/download PDF
14. sj-pdf-1-mdm-10.1177_0272989X211016307 – Supplemental material for Choosing a Metamodel of a Simulation Model for Uncertainty Quantification
- Author
-
de Carvalho, Tiago M., van Rosmalen, Joost, Wolff, Harold B., Koffijberg, Hendrik, and Coupé, Veerle M. H.
- Subjects
111708 Health and Community Services ,111799 Public Health and Health Services not elsewhere classified ,160807 Sociological Methodology and Research Methods ,FOS: Health sciences ,FOS: Sociology - Abstract
Supplemental material, sj-pdf-1-mdm-10.1177_0272989X211016307 for Choosing a Metamodel of a Simulation Model for Uncertainty Quantification by Tiago M. de Carvalho, Joost van Rosmalen, Harold B. Wolff, Hendrik Koffijberg and Veerle M. H. Coupé in Medical Decision Making
- Published
- 2022
- Full Text
- View/download PDF
15. Definition of competence standards for optical diagnosis of diminutive colorectal polyps: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement
- Author
-
Houwen, Britt B. S. L., additional, Hassan, Cesare, additional, Coupé, Veerle M. H., additional, Greuter, Marjolein J. E., additional, Hazewinkel, Yark, additional, Vleugels, Jasper L. A., additional, Antonelli, Giulio, additional, Bustamante-Balén, Marco, additional, Coron, Emmanuel, additional, Cortas, George A., additional, Dinis-Ribeiro, Mario, additional, Dobru, Daniela E., additional, East, James E., additional, Iacucci, Marietta, additional, Jover, Rodrigo, additional, Kuvaev, Roman, additional, Neumann, Helmut, additional, Pellisé, Maria, additional, Puig, Ignasi, additional, Rutter, Matthew D., additional, Saunders, Brian, additional, Tate, David J., additional, Mori, Yuichi, additional, Longcroft-Wheaton, Gaius, additional, Bisschops, Raf, additional, and Dekker, Evelien, additional
- Published
- 2021
- Full Text
- View/download PDF
16. Methodological framework for development of competence standards for optical diagnosis in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement
- Author
-
Houwen, Britt B. S. L., additional, Hassan, Cesare, additional, Hazewinkel, Yark, additional, Vleugels, Jasper L. A., additional, Dinis-Ribeiro, Mario, additional, Greuter, Marjolein J. E., additional, Coupé, Veerle M. H., additional, Dekker, Evelien, additional, and Bisschops, Raf, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative
- Author
-
Puijk, Robbert S., primary, Ahmed, Muneeb, additional, Adam, Andreas, additional, Arai, Yasuaki, additional, Arellano, Ronald, additional, de Baère, Thierry, additional, Bale, Reto, additional, Bellera, Carine, additional, Binkert, Christoph A., additional, Brace, Christopher L., additional, Breen, David J., additional, Brountzos, Elias, additional, Callstrom, Matthew R., additional, Carrafiello, Gianpaolo, additional, Chapiro, Julius, additional, de Cobelli, Francesco, additional, Coupé, Veerle M. H., additional, Crocetti, Laura, additional, Denys, Alban, additional, Dupuy, Damian E., additional, Erinjeri, Joseph P., additional, Filippiadis, Dimitris, additional, Gangi, Afshin, additional, Gervais, Debra A., additional, Gillams, Alice R., additional, Greene, Tissy, additional, Guiu, Boris, additional, Helmberger, Thomas, additional, Iezzi, Roberto, additional, Kang, Tae Wook, additional, Kelekis, Alexis, additional, Kim, Hyun S., additional, Kröncke, Thomas, additional, Kwan, Sharon, additional, Lee, Min Woo, additional, Lee, Fred T., additional, Lee, Edward W., additional, Liang, Ping, additional, Lissenberg-Witte, Birgit I., additional, Lu, David S., additional, Madoff, David C., additional, Mauri, Giovanni, additional, Meloni, Maria Franca, additional, Morgan, Robert, additional, Nadolski, Gregory, additional, Narayanan, Govindarajan, additional, Newton, Isabel, additional, Nikolic, Boris, additional, Orsi, Franco, additional, Pereira, Philippe L., additional, Pua, Uei, additional, Rhim, Hyunchul, additional, Ricke, Jens, additional, Rilling, William, additional, Salem, Riad, additional, Scheffer, Hester J., additional, Sofocleous, Constantinos T., additional, Solbiati, Luigi A., additional, Solomon, Stephen B., additional, Soulen, Michael C., additional, Sze, Daniel, additional, Uberoi, Raman, additional, Vogl, Thomas J., additional, Wang, David S., additional, Wood, Bradford J., additional, Goldberg, S. Nahum, additional, and Meijerink, Martijn R., additional
- Published
- 2021
- Full Text
- View/download PDF
18. A progressive three-state model to estimate time to cancer: a likelihood-based approach.
- Author
-
Akwiwu, Eddymurphy U., Klausch, Thomas, Jodal, Henriette C., Carvalho, Beatriz, Løberg, Magnus, Kalager, Mette, Berkhof, Johannes, H. Coupé, Veerle M., and Coupé, Veerle M H
- Abstract
Background: To optimize colorectal cancer (CRC) screening and surveillance, information regarding the time-dependent risk of advanced adenomas (AA) to develop into CRC is crucial. However, since AA are removed after diagnosis, the time from AA to CRC cannot be observed in an ethically acceptable manner. We propose a statistical method to indirectly infer this time in a progressive three-state disease model using surveillance data.Methods: Sixteen models were specified, with and without covariates. Parameters of the parametric time-to-event distributions from the adenoma-free state (AF) to AA and from AA to CRC were estimated simultaneously, by maximizing the likelihood function. Model performance was assessed via simulation. The methodology was applied to a random sample of 878 individuals from a Norwegian adenoma cohort.Results: Estimates of the parameters of the time distributions are consistent and the 95% confidence intervals (CIs) have good coverage. For the Norwegian sample (AF: 78%, AA: 20%, CRC: 2%), a Weibull model for both transition times was selected as the final model based on information criteria. The mean time among those who have made the transition to CRC since AA onset within 50 years was estimated to be 4.80 years (95% CI: 0; 7.61). The 5-year and 10-year cumulative incidence of CRC from AA was 13.8% (95% CI: 7.8%;23.8%) and 15.4% (95% CI: 8.2%;34.0%), respectively.Conclusions: The time-dependent risk from AA to CRC is crucial to explain differences in the outcomes of microsimulation models used for the optimization of CRC prevention. Our method allows for improving models by the inclusion of data-driven time distributions. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. Choosing a Metamodel of a Simulation Model for Uncertainty Quantification.
- Author
-
de Carvalho, Tiago M., van Rosmalen, Joost, Wolff, Harold B., Koffijberg, Hendrik, and Coupé, Veerle M. H.
- Abstract
Background: Metamodeling may substantially reduce the computational expense of individual-level state transition simulation models (IL-STM) for calibration, uncertainty quantification, and health policy evaluation. However, because of the lack of guidance and readily available computer code, metamodels are still not widely used in health economics and public health. In this study, we provide guidance on how to choose a metamodel for uncertainty quantification. Methods: We built a simulation study to evaluate the prediction accuracy and computational expense of metamodels for uncertainty quantification using life-years gained (LYG) by treatment as the IL-STM outcome. We analyzed how metamodel accuracy changes with the characteristics of the simulation model using a linear model (LM), Gaussian process regression (GP), generalized additive models (GAMs), and artificial neural networks (ANNs). Finally, we tested these metamodels in a case study consisting of a probabilistic analysis of a lung cancer IL-STM. Results: In a scenario with low uncertainty in model parameters (i.e., small confidence interval), sufficient numbers of simulated life histories, and simulation model runs, commonly used metamodels (LM, ANNs, GAMs, and GP) have similar, good accuracy, with errors smaller than 1% for predicting LYG. With a higher level of uncertainty in model parameters, the prediction accuracy of GP and ANN is superior to LM. In the case study, we found that in the worst case, the best metamodel had an error of about 2.1%. Conclusion: To obtain good prediction accuracy, in an efficient way, we recommend starting with LM, and if the resulting accuracy is insufficient, we recommend trying ANNs and eventually also GP regression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Definition of competence standards for optical diagnosis of diminutive colorectal polyps: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.
- Author
-
Houwen, Britt B. S. L., Hassan, Cesare, Coupé, Veerle M. H., Greuter, Marjolein J. E., Hazewinkel, Yark, Vleugels, Jasper L. A., Antonelli, Giulio, Bustamante-Balén, Marco, Coron, Emmanuel, Cortas, George A., Dinis-Ribeiro, Mario, Dobru, Daniela E., East, James E., Iacucci, Marietta, Jover, Rodrigo, Kuvaev, Roman, Neumann, Helmut, Pellisé, Maria, Puig, Ignasi, and Rutter, Matthew D.
- Subjects
COLON polyps ,COLONOSCOPY ,ARTIFICIAL intelligence ,COLORECTAL cancer ,ENDOSCOPIC gastrointestinal surgery - Abstract
BACKGROUND : The European Society of Gastrointestinal Endoscopy (ESGE) has developed a core curriculum for high quality optical diagnosis training for practice across Europe. The development of easy-to-measure competence standards for optical diagnosis can optimize clinical decision-making in endoscopy. This manuscript represents an official Position Statement of the ESGE aiming to define simple, safe, and easy-to-measure competence standards for endoscopists and artificial intelligence systems performing optical diagnosis of diminutive colorectal polyps (1 - 5 mm). METHODS : A panel of European experts in optical diagnosis participated in a modified Delphi process to reach consensus on Simple Optical Diagnosis Accuracy (SODA) competence standards for implementation of the optical diagnosis strategy for diminutive colorectal polyps. In order to assess the clinical benefits and harms of implementing optical diagnosis with different competence standards, a systematic literature search was performed. This was complemented with the results from a recently performed simulation study that provides guidance for setting alternative competence standards for optical diagnosis. Proposed competence standards were based on literature search and simulation study results. Competence standards were accepted if at least 80 % agreement was reached after a maximum of three voting rounds. RECOMMENDATION 1: In order to implement the leave-in-situ strategy for diminutive colorectal lesions (1-5 mm), it is clinically acceptable if, during real-time colonoscopy, at least 90 % sensitivity and 80 % specificity is achieved for high confidence endoscopic characterization of colorectal neoplasia of 1-5 mm in the rectosigmoid. Histopathology is used as the gold standard.Level of agreement 95 %. RECOMMENDATION 2: In order to implement the resect-and-discard strategy for diminutive colorectal lesions (1-5 mm), it is clinically acceptable if, during real-time colonoscopy, at least 80 % sensitivity and 80 % specificity is achieved for high confidence endoscopic characterization of colorectal neoplasia of 1-5 mm. Histopathology is used as the gold standard.Level of agreement 100 %. CONCLUSION : The developed SODA competence standards define diagnostic performance thresholds in relation to clinical consequences, for training and for use when auditing the optical diagnosis of diminutive colorectal polyps. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Methodological framework for development of competence standards for optical diagnosis in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.
- Author
-
Houwen, Britt B. S. L., Hassan, Cesare, Hazewinkel, Yark, Vleugels, Jasper L. A., Dinis-Ribeiro, Mario, Greuter, Marjolein J. E., Coupé, Veerle M. H., Dekker, Evelien, and Bisschops, Raf
- Subjects
ENDOSCOPIC gastrointestinal surgery ,MEDICAL societies - Published
- 2022
- Full Text
- View/download PDF
22. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers.
- Author
-
Jongeneel, Gabrielle, Greuter, Marjolein J. E., Kunst, Natalia, van Erning, Felice N., Koopman, Miriam, Medema, Jan P., Vermeulen, Louis, Ijzermans, Jan N. M., Vink, Geraldine R., Punt, Cornelis J. A., and Coupé, Veerle M. H.
- Abstract
Background: To explore the potential value of consensus molecular subtypes (CMS) in stage II colon cancer treatment selection, we carried out an early cost-effectiveness assessment of a CMS-based strategy for adjuvant chemotherapy. Methods: We used a Markov cohort model to evaluate three selection strategies: (i) the Dutch guideline strategy (MSS+pT4), (ii) the mutation-based strategy (MSS plus a BRAF and/or KRAS mutation or MSS plus pT4), and (iii) the CMS-based strategy (CMS4 or pT4). Outcomes were number of colon cancer deaths per 1,000 patients, total discounted costs per patient (pp), and quality-adjusted life-years (QALY) pp. The analyses were conducted from a Dutch societal perspective. The robustness of model predictions was assessed in sensitivity analyses. To evaluate the value of future research, we performed a value of information (VOI) analysis. Results: The Dutch guideline strategy resulted in 8.10 QALYs pp and total costs of €23,660 pp. The CMS-based and mutation-based strategies were more effective and more costly, with 8.12 and 8.13 QALYs pp and €24,643 and €24,542 pp, respectively. Assuming a threshold of €50,000/QALY, the mutation-based strategy was considered as the optimal strategy in an incremental analysis. However, the VOI analysis showed substantial decision uncertainty driven by the molecular markers (expected value of partial perfect information: €18M). Conclusions: On the basis of current evidence, our analyses suggest that the mutation-based selection strategy would be the best use of resources. However, the extensive decision uncertainty for the molecular markers does not allow selection of an optimal strategy at present. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. A scenario‐drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology.
- Author
-
Kramer, Astrid, Rubio‐Alarcón, Carmen, Broek, Daan, Vessies, Daan C. L., van't Erve, Iris, Meijer, Gerrit A., Vink, Geraldine R., Schuuring, Ed, Fijneman, Remond J. A., Coupé, Veerle M. H., and Retèl, Valesca P.
- Abstract
Circulating tumor DNA (ctDNA) detection has multiple promising applications in oncology, but the road toward implementation in clinical practice is unclear. We aimed to support the implementation process by exploring potential future pathways of ctDNA testing. To do so, we studied four ctDNA‐testing applications in two cancer types and elicited opinions from 30 ctDNA experts in the Netherlands. Our results showed that the current available evidence differed per application and cancer type. Tumor profiling and monitoring treatment response were found most likely to be implemented in non‐small cell lung cancer (NSCLC) within 5 years. For colorectal cancer, applications of ctDNA testing were found to be at an early stage in the implementation process. Demonstrating clinical utility was found a key aspect for successful implementation, but there was no consensus regarding the evidence requirements. The next step toward implementation is to define how clinical utility of biomarkers should be evaluated. Finally, these data indicate that specific challenges for each clinical application and tumor type should be appropriately addressed in a deliberative process involving all stakeholders to ensure implementation of ctDNA testing and timely access for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Fitting a progressive three-state colorectal cancer model to interval-censored surveillance data under outcome-dependent sampling using a weighted likelihood approach.
- Author
-
Akwiwu EU, Klausch T, Jodal HC, Carvalho B, Løberg M, Kalager M, Berkhof J, and Coupé VMH
- Abstract
To optimize colorectal cancer (CRC) surveillance, accurate information on the risk of developing CRC from premalignant lesions is essential. However, directly observing this risk is challenging since precursor lesions, i.e., advanced adenomas (AAs), are removed upon detection. Statistical methods for multistate models can estimate risks, but estimation is challenging due to low CRC incidence. We propose an outcome-dependent sampling (ODS) design for this problem in which we oversample CRCs. More specifically, we propose a three-state model for jointly estimating the time distributions from baseline colonoscopy to AA and from AA onset to CRC accounting for the ODS design using a weighted likelihood approach. We applied the methodology to a sample from a Norwegian adenoma cohort (1993-2007), comprising 1, 495 individuals (median follow-up 6.8 years [IQR: 1.1 - 12.8 years]) of whom 648 did and 847 did not develop CRC. We observed a 5-year AA risk of 13% and 34% for individuals having non-advanced adenoma (NAA) and AA removed at baseline colonoscopy, respectively. Upon AA development, the subsequent risk to develop CRC in 5 years was 17% and age-dependent. These estimates provide a basis for optimizing surveillance intensity and determining the optimal trade-off between CRC prevention, costs, and use of colonoscopy resources., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
25. Stool-based testing for post-polypectomy colorectal cancer surveillance safely reduces colonoscopies: The MOCCAS study.
- Author
-
Carvalho B, de Klaver W, van Wifferen F, van Lanschot MCJ, van Wetering AJP, van der Zander QEW, Lemmens M, Bolijn AS, Tijssen M, Diemen PD, Buekers N, Daenen K, van der Meer J, van Mulligen PG, Hijmans BS, de Ridder S, Meiqari L, Bierkens M, van der Hulst RWM, Kuyvenhoven JPH, van Berkel AM, Depla ACTM, van Leerdam ME, Jansen JM, Wientjes CA, Straathof JA, Keulen ETP, Ramsoekh D, Moons LMG, Zacherl M, Masclee AAM, de Wit M, Greuter MJE, van Engeland M, Dekker E, Coupé VMH, and Meijer GA
- Abstract
Background and Aims: Colonoscopy-based surveillance to prevent colorectal cancer (CRC) causes substantial burden for patients and healthcare. Stool tests may help to reduce surveillance colonoscopies, by limiting colonoscopies to individuals at increased risk of AN., Methods: This cross-sectional observational study included individuals aged 50-75 with surveillance indication. Before bowel preparation, participants collected samples for a multitarget stool DNA (mt-sDNA) test and two fecal immunochemical tests (FITs). Test accuracies were calculated for all surveillance indications. Only for the post-polypectomy indication, most common and associated with a relatively low CRC risk, long-term impact of stool-based surveillance was evaluated with the ASCCA model. Stool-based strategies were simulated to tune each tests' positivity threshold to obtain strategies at least as effective as colonoscopy surveillance., Results: 3453 individuals had results for all stool tests and colonoscopy. 2226 had previous polypectomy, 1003 previous CRC and 224 familial risk. Areas under the receiver operating characteristic curve for AN were 0.72 (95% CI; 0.69-0.75) for the mt-sDNA test, 0.61 (95% CI; 0.58-0.64) for the FIT OC-Sensor and 0.59 (95% CI; 0.56-0.61) for the FIT FOB-Gold. Stool-based post-polypectomy surveillance strategies at least as effective as colonoscopy surveillance, reduced the number of colonoscopies by 15-41% and required 5.6-9.5 stool tests over the lifetime of a person. Mt-sDNA-based surveillance was more costly than colonoscopy surveillance, whereas FIT-based surveillance saved costs., Conclusions: This study shows that stool-based post-polypectomy surveillance strategies can be safe and cost-effective, with potential to reduce the number of colonoscopies by up to 41%., (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Healthcare cost expenditure for robotic versus laparoscopic liver resection: a bottom-up economic evaluation.
- Author
-
Pilz da Cunha G, Coupé VMH, Zonderhuis BM, Bonjer HJ, Erdmann JI, Kazemier G, Besselink MG, and Swijnenburg RJ
- Subjects
- Humans, Male, Retrospective Studies, Female, Middle Aged, Aged, Hospital Costs, Cost-Benefit Analysis, Operative Time, Health Care Costs, Treatment Outcome, Time Factors, Laparoscopy economics, Hepatectomy economics, Robotic Surgical Procedures economics, Health Expenditures
- Abstract
Background: Minimally invasive liver surgery (MILS) is increasingly performed via the robot-assisted approach but may be associated with increased costs. This study is a post-hoc comparison of healthcare cost expenditure for robotic liver resection (RLR) and laparoscopic liver resection (LLR) in a high-volume center., Methods: In-hospital and 30-day postoperative healthcare costs were calculated per patient in a retrospective series (October 2015-December 2022)., Results: Overall, 298 patients were included (143 RLR and 155 LLR). Benefits of RLR were lower conversion rate (2.8% vs 12.3%, p = 0.002), shorter operating time (167 min vs 198 min, p = 0.044), and less blood loss (50 mL vs 200 mL, p < 0.001). Total per-procedure costs of RLR (€10260) and LLR (€9931) were not significantly different (mean difference €329 [95% bootstrapped confidence interval (BCI) €-1179-€2120]). Lower costs with RLR due to shorter surgical and operating room time were offset by higher disposable instrumentation costs resulting in comparable intraoperative costs (€5559 vs €5247, mean difference €312 [95% BCI €-25-€648]). Postoperative costs were similar for RLR (€4701) and LLR (€4684), mean difference €17 [95% BCI €-1357-€1727]. When also considering purchase and maintenance costs, RLR resulted in higher total per-procedure costs., Discussion: In a high-volume center, RLR can have similar per-procedure cost expenditure as LLR when disregarding capital investment., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Benefit-Harm Analysis for Informed Decision Making on Participating in Colorectal Cancer Screening: A Modeling Study.
- Author
-
Yebyo HG, van Wifferen F, Pluymen LPM, Leeflang MMG, Dekker E, Coupé VMH, Puhan MA, Greuter MJE, and Stegeman I
- Subjects
- Male, Humans, Female, Aged, Infant, Decision Making, Mass Screening, Early Detection of Cancer, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology
- Abstract
Objectives: To facilitate informed decision making on participating in colorectal cancer (CRC) screening, we assessed the benefit-harm balance of CRC screening for a wide range of subgroups over different time horizons., Methods: The study combined incidence proportions of benefits and harms of (not) participating in CRC screening estimated by the Adenoma and Serrated pathway to CAncer microsimulation model, a preference eliciting survey, and benefit-harm balance modeling combining all outcomes to determine the net health benefit of CRC screening over 10, 20, and 30 years. Probability of net health benefit was estimated for 210 different subgroups based on age, sex, previous participation in CRC screening, and lifestyle., Results: CRC screening was net beneficial in 183 of 210 subgroups over 30 years (median probability [MP] of 0.79, interquartile range [IQR] of 0.69-0.85) across subgroups. Net health benefit was greater for men (MP 0.82; IQR 0.69-0.89) than women (MP 0.76; IQR 0.67-0.83) and for those without history of participation in previous screenings (MP 0.84; IQR 0.80-0.89) compared with those with (MP 0.69; IQR 0.59-0.75). Net health benefit decreased with increasing age, from MP of 0.84 (IQR 0.80-0.86) at age 55 to 0.61 (IQR 0.56-0.71) at age 75. Shorter time horizons led to lower benefit, with MP of 0.70 (IQR 0.62-0.80) over 20 years and 0.54 (IQR 0.48-0.67) over 10 years., Conclusions: Our benefit-harm analysis provides information about net health benefit of screening participation, based on important characteristics and preferences of individuals, which could assist screening invitees in making informed decisions on screening participation., Competing Interests: Author Disclosures Links to the individual disclosure forms provided by the authors are available here., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
28. Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II-III Colorectal Cancer: A Population-based Study.
- Author
-
Boute TC, Swartjes H, Greuter MJE, Elferink MAG, van Eekelen R, Vink GR, de Wilt JHW, and Coupé VMH
- Subjects
- Humans, Incidence, Neoplasm Staging, Neoplasm Recurrence, Local epidemiology, Risk Factors, Colorectal Neoplasms epidemiology, Colonic Neoplasms epidemiology, Rectal Neoplasms drug therapy
- Abstract
Real-world data are necessitated to counsel patients about the risk for recurrent disease after curative treatment of colorectal cancer. This study provided a population-based overview of the epidemiology of recurrent disease in patients with surgically resected stage II/III colorectal cancer.Patients diagnosed with stage II/III primary colorectal cancer between July and December 2015 were selected from the Netherlands Cancer Registry (N = 3,762). Cumulative incidence of recurrent disease was estimated, and multivariable competing risk regression was used to identify risk factors for recurrent disease in patients with primary colon and rectal cancer. Moreover, overall survival (OS) after diagnosis of recurrent colorectal cancer was estimated.Median clinical follow-up was 58 months (Q1-Q3: 22-62). Five-year cumulative incidence of recurrent disease was 21.6% [95% confidence interval (CI): 20.0-23.2] and 30.0% (95% CI: 28.3-33.5) for patients with primary colon and rectal cancer, respectively. Stage III disease and incomplete resection margin in patients with primary colon cancer and extramural vascular invasion in patients with primary rectal cancer were strongly (HR ≥ 2) associated with recurrent disease. Median OS of patients with distant, locoregional, or the synchronous combination of distant and locoregional recurrent disease was 29, 27, and 13 months, respectively (P < 0.001). Patients with distant recurrences limited to liver or lung showed a median OS of 46 and 48 months, respectively. The incidence of recurrent disease was higher in patients with rectal cancer than in patients with colon cancer, predominantly due to higher rates of distant recurrences. OS after recurrent disease was impaired, but subgroups of patients diagnosed with recurrent disease limited to one site showed statistically significantly longer OS., Significance: Population-based data on recurrent colorectal cancer are rare, but crucial for counseling patients and their physicians. This large nationwide, population-based study provides an up-to-date overview of the epidemiology of recurrent disease in patients with stage II and III primary colon and rectal cancer treated with surgical resection., (© 2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
29. Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case-Control Study.
- Author
-
Jodal HC, Akwiwu EU, Lemmens M, Delis-van Diemen PM, Klotz D, Leon LG, Lakbir S, de Wit M, Fijneman RJA, van Leerdam ME, Dekker E, Spaander MCW, Meijer GA, Løberg M, Coupé VMH, Kalager M, and Carvalho B
- Subjects
- Humans, Case-Control Studies, DNA, Colorectal Neoplasms diagnosis, Adenoma diagnosis, Carcinoma
- Abstract
Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may result in suboptimal surveillance. Certain DNA copy-number alterations (CNAs) are associated with adenoma-to-carcinoma progression. We aimed to evaluate whether these molecular features can better predict an individual's risk of me-CRC than the morphologic advanced adenoma features.In this nested case-control study, 529 individuals with a single adenoma at first colonoscopy were selected from a Norwegian adenoma cohort. DNA copy-number profiles were determined, by low-coverage whole-genome sequencing. Prevalence of CNAs in advanced and non-advanced adenomas and its association (OR) with me-CRC was assessed. For the latter, cases (with me-CRC) were matched to controls (without me-CRC) on follow-up, age and sex.CNAs associated with adenoma-to-carcinoma progression were observed in 85/267 (32%) of advanced adenomas and in 27/262 (10%) of non-advanced adenomas. me-CRC was statistically significantly associated, also after adjustment for other variables, with age at baseline [OR, 1.14; 95% confidence interval CI), 1.03-1.26; P = 0.012], advanced adenomas (OR, 2.46; 95% CI, 1.50-4.01; P < 0.001) and with the presence of ≥3 DNA copy-number losses (OR, 1.90; 95% CI. 1.02-3.54; P = 0.043).Molecularly-defined high-risk adenomas were associated with me-CRC, but the association of advanced adenoma with me-CRC was stronger., Significance: Identifying new biomarkers may improve prediction of me-CRC for individuals with adenomas and optimize surveillance intervals to reduce risk of colorectal cancer and reduce oversurveillance of patients with low risk of colorectal cancer. Use of DNA CNAs alone does not improve prediction of me-CRC. Further research to improve risk classification is required., (© 2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
30. Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.
- Author
-
Worthington J, van Wifferen F, Sun Z, de Jonge L, Lew JB, Greuter MJE, van den Puttelaar R, Feletto E, Lansdorp-Vogelaar I, Coupé VMH, Ein Yong JH, and Canfell K
- Abstract
Background: Screening for colorectal cancer (CRC) decreases cancer burden through removal of precancerous lesions and early detection of cancer. The COVID-19 pandemic has disrupted organised CRC screening programs worldwide, with some programs completely suspending screening and others experiencing significant decreases in participation and diagnostic follow-up. This study estimated the global impact of screening disruptions on CRC outcomes, and potential effects of catch-up screening., Methods: Organised screening programs were identified in 29 countries, and data on participation rates and COVID-related changes to screening in 2020 were extracted where available. Four independent microsimulation models (ASCCA, MISCAN-Colon, OncoSim, and Policy1-Bowel) were used to estimate the long-term impact on CRC cases and deaths, based on decreases to screening participation in 2020. For countries where 2020 participation data were not available, changes to screening were approximated based on excess mortality rates. Catch-up strategies involving additional screening in 2021 were also simulated., Findings: In countries for which direct data were available, organised CRC screening volumes at a country level decreased by an estimated 1.3-40.5% in 2020. Globally, it is estimated that COVID-related screening decreases led to a deficit of 7.4 million fewer faecal screens performed in 2020. In the absence of any organised catch-up screening, this would lead to an estimated 13,000 additional CRC cases and 7,900 deaths globally from 2020 to 2050; 79% of the additional cases and 85% of additional deaths could have been prevented with catch-up screening, respectively., Interpretation: COVID-19-related disruptions to screening will cause excess CRC cases and deaths, but appropriately implemented catch-up screening could have reduced the burden by over 80%. Careful management of any disruption is key to improving the resilience of colorectal cancer screening programs., Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Cancer Council New South Wales, Health Canada, and Dutch National Institute for Public Health and Environment., Competing Interests: Karen Canfell is co-PI of an investigator-initiated trial of cervical screening, “Compass”, run by the Australian Centre for Prevention of Cervical Cancer (ACPCC), which is a government-funded not-for-profit charity. Compass receives infrastructure support from the Australian government and the ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics, USA. Karen Canfell is co-PI on a major implementation program Elimination of Cervical Cancer in the Western Pacific which has received support from the Minderoo Foundation and the Frazer Family Foundation and equipment donations from Cepheid Inc. Dr. Lew reports grants from National Health and Medical Research Council, during the conduct of the study. Dr. Feletto reports grants from National Health and Medical Research Council, outside the submitted work. Dr Coupé reports grants from Dutch Cancer Foundation, grants from Netherlands Organisation for Health Research and Development, and from Maag Lever Darm Stichting MLDS, outside the submitted work., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
31. A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice.
- Author
-
Kramer A, Schuuring E, Vessies DCL, van der Leest P, Geerlings MJ, Rozendal P, Lanfermeijer M, Linders TC, van Kempen LC, Fijneman RJA, Ligtenberg MJL, Meijer GA, van den Broek D, Retèl VP, and Coupé VMH
- Subjects
- Humans, High-Throughput Nucleotide Sequencing, Polymerase Chain Reaction, Biomarkers, Tumor genetics, Circulating Tumor DNA genetics
- Abstract
Circulating tumor DNA (ctDNA) is a promising new biomarker with multiple potential applications in cancer care. Estimating total cost of ctDNA testing is necessary for reimbursement and implementation, but challenging because of variations in workflow. We aimed to develop a micro-costing framework for consistent cost calculation of ctDNA testing. First, the foundation of the framework was built, based on the complete step-wise diagnostic workflow of ctDNA testing. Second, the costing method was set up, including costs for personnel, materials, equipment, overhead, and failures. Third, the framework was evaluated by experts and applied to six case studies, including PCR-, mass spectrometry-, and next-generation sequencing-based platforms, from three Dutch hospitals. The developed ctDNA micro-costing framework includes the diagnostic workflow from blood sample collection to diagnostic test result. The framework was developed from a Dutch perspective and takes testing volume into account. An open access tool is provided to allow for laboratory-specific calculations to explore the total costs of ctDNA testing specific workflow parameters matching the setting of interest. It also allows to straightforwardly assess the impact of alternative prices or assumptions on the cost per sample by simply varying the input parameters. The case studies showed a wide range of costs, from €168 to €7638 ($199 to $9124) per sample, and generated information. These costs are sensitive to the (coverage of) platform, setting, and testing volume., (Copyright © 2023 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
32. Guidance for setting international standards on reporting longitudinal adherence to stool-based colorectal cancer screening.
- Author
-
van Wifferen F, Greuter MJE, Lissenberg-Witte BI, Carvalho B, Meijer GA, Dekker E, Campari C, Garcia M, Rabeneck L, Lansdorp-Vogelaar I, Senore C, and Coupé VMH
- Subjects
- Humans, Consensus, Feces, Italy epidemiology, Spain epidemiology, Netherlands epidemiology, Colorectal Neoplasms diagnosis, Colorectal Neoplasms prevention & control, Early Detection of Cancer
- Abstract
Longitudinal adherence to colorectal cancer (CRC) screening is reported using different summarizing measures, which hampers international comparison. We provide evidence to guide recommendations on which longitudinal adherence measure to report. Using adherence data over four stool-based CRC screening rounds in three countries, we calculated six summarizing adherence measures; adherence over all rounds, adherence per round, rescreening, full programme adherence (yes/no), regularity (never/inconsistent/consistent screenees) and number of times participated. For each measure, we calculated the accuracy in capturing the observed adherence patterns. Using the ASCCA model, we predicted screening effectiveness when using summarizing measures as model input versus the observed adherence patterns. Adherence over all rounds in the Italian, Spanish and Dutch cohorts was 64.9%, 42.8% and 61.5%, respectively, and the proportion of consistent screenees was 50.9%, 26.3% and 45.7%. Number of times participated and regularity were most accurate and resulted in similar model-predicted screening effectiveness as simulating the observed adherence patterns of Italy, Spain and the Netherlands (mortality reductions: 24.4%, 16.9% and 23.5%). Adherence over all rounds and adherence per round were least accurate. Screening effectiveness was overestimated when using adherence over all rounds (mortality reductions: 26.8%, 19.4% and 25.7%) and adherence per round (mortality reductions: 26.8%, 19.5% and 25.9%). To conclude, number of times participated and regularity were most accurate and resulted in similar model-predicted screening effectiveness as using the observed adherence patterns. However they require longitudinal data. To facilitate international comparison of CRC screening programme performance, consensus on an accurate adherence measure to report should be reached., Competing Interests: Declaration of Competing Interest Beatriz Carvalho is inventor on several biomarker patents pending. GA Meijer is co-founder and board member (CSO) of CRCbioscreen BV, he has a research collaboration with CZ Health Insurances (cash matching to ZonMW grant) and he has research collaborations with Exact Sciences, Sysmex, Sentinel Ch. SpA, Personal Genome Diagnostics (PGDX), DELFI and Hartwig Medical Foundation; these companies provide materials, equipment and/or sample/genomic analyses. Evelien Dekker has endoscopic equipment on loan of FujiFilm and Olympus, received a research grant from FujiFilm, and received honorarium for consultancy from FujiFilm, Olympus, GI Supply, CPP-FAP, PAION and Ambu, and speakers' fees from Olympus, GI Supply, Norgine, IPSEN, PAION and FujiFilm., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
- Author
-
Wolff HB, Qendri V, Kunst N, Alarid-Escudero F, and Coupé VMH
- Subjects
- Cost-Benefit Analysis, Humans, Probability, Uncertainty, Health Policy
- Abstract
Purpose: Analyzing and communicating uncertainty is essential in medical decision making. To judge whether risks are acceptable, policy makers require information on the expected outcomes but also on the uncertainty and potential losses related to the chosen strategy. We aimed to compare methods used to represent the impact of uncertainty in decision problems involving many strategies, enhance existing methods, and provide an open-source and easy-to-use tool., Methods: We conducted a systematic literature search to identify methods used to represent the impact of uncertainty in cost-effectiveness analyses comparing multiple strategies. We applied the identified methods to probabilistic sensitivity analysis outputs of 3 published decision-analytic models comparing multiple strategies. Subsequently, we compared the following characteristics: type of information conveyed, use of a fixed or flexible willingness-to-pay threshold, output interpretability, and the graphical discriminatory ability. We further proposed adjustments and integration of methods to overcome identified limitations of existing methods., Results: The literature search resulted in the selection of 9 methods. The 3 methods with the most favorable characteristics to compare many strategies were 1) the cost-effectiveness acceptability curve (CEAC) and cost-effectiveness acceptability frontier (CEAF), 2) the expected loss curve (ELC), and 3) the incremental benefit curve (IBC). The information required to assess confidence in a decision often includes the average loss and the probability of cost-effectiveness associated with each strategy. Therefore, we proposed the integration of information presented in an ELC and CEAC into a single heat map., Conclusions: This article presents an overview of methods presenting uncertainty in multiple-strategy cost-effectiveness analyses, with their strengths and shortcomings. We proposed a heat map as an alternative method that integrates all relevant information required for health policy and medical decision making., Highlights: To assess confidence in a chosen course of action, decision makers require information on both the probability and the consequences of making a wrong decision.This article contains an overview of methods for presenting uncertainty in multiple-strategy cost-effectiveness analyses.We propose a heat map that combines the probability of cost-effectiveness from the cost-effectiveness acceptability curve (CEAC) with the consequences of a wrong decision from the expected loss curve.Collapsing of the CEAC can be reduced by relaxing the CEAC, as proposed in this article.Code in Microsoft Excel and R is provided to easily analyze data using the methods discussed in this article.
- Published
- 2022
- Full Text
- View/download PDF
34. The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome.
- Author
-
Kang YJ, Caruana M, McLoughlin K, Killen J, Simms K, Taylor N, Frayling IM, Coupé VMH, Boussioutas A, Trainer AH, Ward RL, Macrae F, and Canfell K
- Subjects
- Adult, Aged, Australia, Colonoscopy, Cost-Benefit Analysis, DNA Mismatch Repair genetics, Humans, Middle Aged, Mismatch Repair Endonuclease PMS2 genetics, MutL Protein Homolog 1 genetics, MutS Homolog 2 Protein genetics, Colorectal Neoplasms, Hereditary Nonpolyposis diagnosis, Colorectal Neoplasms, Hereditary Nonpolyposis epidemiology, Colorectal Neoplasms, Hereditary Nonpolyposis genetics
- Abstract
Purpose: Lynch syndrome-related colorectal cancer (CRC) risk substantially varies by mismatch repair (MMR) gene. We evaluated the health impact and cost-effectiveness of MMR gene-tailored colonoscopic surveillance., Methods: We first estimated sex- and MMR gene-specific cumulative lifetime risk of first CRC without colonoscopic surveillance using an optimization algorithm. Next, we harnessed these risk estimates in a microsimulation model, "Policy1-Lynch," and compared 126 colonoscopic surveillance strategies against no surveillance., Results: The most cost-effective strategy was 3-yearly surveillance from age 25 to 70 years (pathogenic variants [path_] in MLH1 [path_MLH1], path_MSH2) with delayed surveillance for path_MSH6 (age 30-70 years) and path_PMS2 (age 35-70 years) heterozygotes (incremental cost-effectiveness ratio = Australian dollars (A) $8,833/life-year saved). This strategy averted 60 CRC deaths (153 colonoscopies per death averted) over the lifetime of 1000 confirmed patients with Lynch syndrome (vs no surveillance). This also reduced colonoscopies by 5% without substantial change in health outcomes (vs nontailored 3-yearly surveillance from 25-70 years). Generally, starting surveillance at age 25 (vs 20) years was more cost-effective with minimal effect on life-years saved and starting 5 to 10 years later for path_MSH6 and path_PMS2 heterozygotes (vs path_MLH1 and path_MSH2) further improved cost-effectiveness. Surveillance end age (70/75/80 years) had a minor effect. Three-yearly surveillance strategies were more cost-effective (vs 1 or 2-yearly) but prevented 3 fewer CRC deaths., Conclusion: MMR gene-specific colonoscopic surveillance would be effective and cost-effective., Competing Interests: Conflict of Interest K.C. is co–principle investigator of an investigator-initiated trial of cervical screening, “Compass”, run by The Australian Centre for the Prevention of Cervical Cancer (ACPCC), which is a government-funded not-for-profit charity; “Compass” receives infrastructure support from the Australian government and the ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics, USA. She is also co–principle investigator on a major implementation program Elimination of Cervical Cancer in the Western Pacific which has received support from the Minderoo Foundation and the Frazer Family Foundation, and equipment donations from Cepheid Inc. She also receives support for a range of other Australian and international government projects including support from philanthropic organizations, WHO, and government agencies related to cervical cancer control. K.C. is a Chair or member of a number of government or meetings convened by the World Health Organization (WHO), or philanthropic organizations such as Bill and Melinda Gates Foundation (BMGF). N.T. is a recipient of a Cancer Institute NSW Career Development Fellowship and a Cancer Australia Priority-driven Collaborative Cancer Research Scheme project grant. All other authors declare no conflicts of interest., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
35. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands.
- Author
-
Wolff HB, Steeghs EMP, Mfumbilwa ZA, Groen HJM, Adang EM, Willems SM, Grünberg K, Schuuring E, Ligtenberg MJL, Tops BBJ, and Coupé VMH
- Subjects
- Cost-Benefit Analysis, Humans, Netherlands epidemiology, Quality of Life, Carcinoma, Non-Small-Cell Lung diagnosis, Lung Neoplasms diagnosis
- Abstract
Purpose: A large number of targeted treatment options for stage IV nonsquamous non-small-cell lung cancer with specific genetic aberrations in tumor DNA is available. It is therefore important to optimize diagnostic testing strategies, such that patients receive adequate personalized treatment that improves survival and quality of life. The aim of this study is to assess the efficacy (including diagnostic costs, turnaround time (TAT), unsuccessful tests, percentages of correct findings, therapeutic costs, and therapeutic effectiveness) of parallel next generation sequencing (NGS)-based versus sequential single-gene-based testing strategies routinely used in patients with metastasized non-small-cell lung cancer in the Netherlands., Methods: A diagnostic microsimulation model was developed to simulate 100,000 patients with prevalence of genetic aberrations, extracted from real-world data from the Dutch Pathology Registry. These simulated patients were modeled to undergo different testing strategies composed of multiple tests with different test characteristics including single-gene and panel tests, test accuracy, the probability of an unsuccessful test, and TAT. Diagnostic outcomes were linked to a previously developed treatment model, to predict average long-term survival, quality-adjusted life-years (QALYs), costs, and cost-effectiveness of parallel versus sequential testing., Results: NGS-based parallel testing for all actionable genetic aberrations is on average €266 cheaper than single-gene-based sequential testing, and detects additional relevant targetable genetic aberrations in 20.5% of the cases, given a TAT of maximally 2 weeks. Therapeutic costs increased by €8,358, and 0.12 QALYs were gained, leading to an incremental cost-effectiveness ratio of €69,614/QALY for parallel versus sequential testing., Conclusion: NGS-based parallel testing is diagnostically superior over single-gene-based sequential testing, as it is cheaper and more effective than sequential testing. Parallel testing remains cost-effective with an incremental cost-effectiveness ratio of 69,614 €/QALY upon inclusion of therapeutic costs and long-term outcomes.
- Published
- 2022
- Full Text
- View/download PDF
36. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
- Author
-
van Wifferen F, de Jonge L, Worthington J, Greuter MJE, Lew JB, Nadeau C, van den Puttelaar R, Feletto E, Yong JHE, Lansdorp-Vogelaar I, Canfell K, and Coupé VMH
- Subjects
- Colonoscopy, Early Detection of Cancer, Feces, Humans, Mass Screening, Occult Blood, Pandemics, COVID-19, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology
- Abstract
Objectives: Colorectal cancer (CRC) screening with a faecal immunochemical test (FIT) has been disrupted in many countries during the COVID-19 pandemic. Performing catch-up of missed screens while maintaining regular screening services requires additional colonoscopy capacity that may not be available. This study aimed to compare strategies that clear the screening backlog using limited colonoscopy resources., Methods: A range of strategies were simulated using four country-specific CRC natural-history models: Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) and MIcrosimulation SCreening ANalysis for CRC (MISCAN-Colon) (both in the Netherlands), Policy1-Bowel (Australia) and OncoSim (Canada). Strategies assumed a 3-month screening disruption with varying recovery period lengths (6, 12, and 24 months) and varying FIT thresholds for diagnostic colonoscopy. Increasing the FIT threshold reduces the number of referrals to diagnostic colonoscopy. Outcomes for each strategy were colonoscopy demand and excess CRC-related deaths due to the disruption., Results: Performing catch-up using the regular FIT threshold in 6, 12 and 24 months could prevent most excess CRC-related deaths, but required 50%, 25% and 12.5% additional colonoscopy demand, respectively. Without exceeding usual colonoscopy demand, up to 60% of excess CRC-related deaths can be prevented by increasing the FIT threshold for 12 or 24 months. Large increases in FIT threshold could lead to additional deaths rather than preventing them., Conclusions: Clearing the screening backlog in 24 months could avert most excess CRC-related deaths due to a 3-month disruption but would require a small increase in colonoscopy demand. Increasing the FIT threshold slightly over 24 months could ease the pressure on colonoscopy resources.
- Published
- 2022
- Full Text
- View/download PDF
37. Guidance for setting easy-to-adopt competence criteria for optical diagnosis of diminutive colorectal polyps: a simulation approach.
- Author
-
Houwen BBSL, Greuter MJE, Vleugels JLA, Hazewinkel Y, Bisschops R, Dekker E, and Coupé VMH
- Subjects
- Colon pathology, Colonoscopy, Humans, Narrow Band Imaging, Predictive Value of Tests, Rectum, Adenoma diagnostic imaging, Adenoma pathology, Colonic Polyps diagnostic imaging, Colonic Polyps pathology, Colorectal Neoplasms diagnostic imaging, Colorectal Neoplasms pathology
- Abstract
Background and Aims: One reason the optical diagnosis strategy for diminutive colorectal polyps has not yet been implemented is that the current competence criteria (Preservation and Incorporation of Valuable Endoscopic Innovation [PIVI] initiative) are difficult to use in daily practice. To provide guidance for setting alternative easy-to-adopt competence criteria, we determined the lowest proportion of diminutive polyps that should have a correct optical diagnosis to meet the PIVI., Methods: For this simulation study, we used datasets from 2 prospectively collected cohorts of patients who underwent colonoscopy in either a primary colonoscopy or fecal immunochemical test (FIT) screening setting. In the simulation approach, virtual endoscopists or computer-aided diagnosis systems performed optical diagnosis of diminutive polyps with a fixed diagnostic performance level (strategy) on all individuals in the cohort who had ≥1 diminutive polyp. Strategies were defined by systematically varying the proportion of correct optical diagnoses for each polyp subtype (ie, adenomas, hyperplastic polyps, sessile serrated lesions). For each strategy, we determined whether PIVI-1 (≥90% agreement with U.S. or European Society for Gastrointestinal Endoscopy [ESGE] surveillance guidelines) and PIVI-2 (≥90% negative predictive value [NPV] for neoplastic lesions in the rectosigmoid) were met using Monte Carlo sampling with 1000 repetitions, with histology as reference., Results: The level of overall diagnostic accuracy to achieve the PIVI differed significantly depending on the clinical setting and guidelines used. In the colonoscopy screening setting, all diagnostic strategies in which 92% of all diminutive polyps (regardless of histology) were diagnosed correctly led to 90% or more agreement with U.S. surveillance intervals (ie, PIVI-1). For all diagnostic strategies in which ≥89% of all diminutive polyps were correctly diagnosed, at least 90% NPV was achieved (ie, PIVI-2). For the FIT screening setting, values were respectively ≥77% and ≥94%. When using ESGE guidelines, PIVI-1 was in both settings already met when 40% of all diminutive polyps were diagnosed correctly., Conclusions: In contrast to the fixed PIVI criteria, our simulation study shows that different thresholds for the proportion of correctly diagnosed diminutive polyps lead to different clinical consequences depending on guidelines and clinical setting. However, this target proportion of diminutive colorectal polyps correctly diagnosed with optical diagnosis represents easier-to-adopt competence criteria., (Copyright © 2021 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening : A Diagnostic Test Accuracy Study.
- Author
-
de Klaver W, Wisse PHA, van Wifferen F, Bosch LJW, Jimenez CR, van der Hulst RWM, Fijneman RJA, Kuipers EJ, Greuter MJE, Carvalho B, Spaander MCW, Dekker E, Coupé VMH, de Wit M, and Meijer GA
- Subjects
- Aged, Biomarkers, Tumor chemistry, Colonoscopy, Early Detection of Cancer, Female, Humans, Male, Middle Aged, Colorectal Neoplasms diagnosis, Diagnostic Tests, Routine standards, Feces chemistry, Mass Screening instrumentation
- Abstract
Background: The fecal immunochemical test (FIT) is used in colorectal cancer (CRC) screening, yet it leaves room for improvement., Objective: To develop a multitarget FIT (mtFIT) with better diagnostic performance than FIT., Design: Diagnostic test accuracy study., Setting: Colonoscopy-controlled series., Participants: Persons ( n = 1284) from a screening ( n = 1038) and referral ( n = 246) population were classified by their most advanced lesion (CRC [ n = 47], advanced adenoma [ n = 135], advanced serrated polyp [ n = 30], nonadvanced adenoma [ n = 250], and nonadvanced serrated polyp [ n = 53]), along with control participants ( n = 769)., Measurements: Antibody-based assays were developed and applied to leftover FIT material. Classification and regression tree (CART) analysis was applied to biomarker concentrations to identify the optimal combination for detecting advanced neoplasia. Performance of this combination, the mtFIT, was cross-validated using a leave-one-out approach and compared with FIT at equal specificity., Results: The CART analysis showed a combination of hemoglobin, calprotectin, and serpin family F member 2-the mtFIT-to have a cross-validated sensitivity for advanced neoplasia of 42.9% (95% CI, 36.2% to 49.9%) versus 37.3% (CI, 30.7% to 44.2%) for FIT ( P = 0.025), with equal specificity of 96.6%. In particular, cross-validated sensitivity for advanced adenomas increased from 28.1% (CI, 20.8% to 36.5%) to 37.8% (CI, 29.6% to 46.5%) ( P = 0.006). On the basis of these results, early health technology assessment indicated that mtFIT-based screening could be cost-effective compared with FIT., Limitation: Study population is enriched with persons from a referral population., Conclusion: Compared with FIT, the mtFIT showed better diagnostic accuracy in detecting advanced neoplasia because of an increased detection of advanced adenomas. Moreover, early health technology assessment indicated that these results provide a sound basis to pursue further development of mtFIT as a future test for population-based CRC screening. A prospective screening trial is in preparation., Primary Funding Source: Stand Up to Cancer/Dutch Cancer Society, Dutch Digestive Foundation, and HealthHolland.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.